364077-84-9

Usage

InChI:InChI=1/C11H17NO5/c1-11(2,3)17-10(15)12-6-7(13)5-8(12)9(14)16-4/h8H,5-6H2,1-4H3/t8-/m0/s1

Upstream product

• 135042-12-5 (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-D-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2584-71-6 cis-hydroxy-D-proline 

Downstream Products

• 773889-45-5 (R)-4-oxo-2-[4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1157846-12-2 C₁₆H₂₀FNO₅ 
• 1157846-07-5 C₁₇H₂₃NO₅ 
• 1157846-08-6 C₁₇H₂₃NO₅ 
• 1157846-06-4 (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxy-4-phenylpyrrolidine-2-carboxylic acid 
• 1157846-13-3 C₁₆H₁₉F₂NO₅ 
• 1157846-10-0 C₁₇H₂₀F₃NO₅ 
• 1157846-14-4 (2R,4S)-1-(tert-butoxycarbonyl)-4-(2,4-difluorophenyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 1157846-09-7 C₁₇H₂₃NO₅ 
• 1157846-11-1 C₁₆H₂₀ClNO₅ 

Relevant academic research and scientific papers

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula (I) or (IA) compositions comprising compounds of Formula (I) or (IA), and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula (I) or (IA) to a patient in need thereof:

Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action

Aiming to improve upon previously disclosed Factor Xa inhibitors, a series of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides were explored with the intent of increasing the projected human half-life versus 5 (projected human t1/2 = 6 h). A stereospecific route to compounds containing a 4-aryl-4-hydroxypyrrolidine scaffold was developed, resulting in several compounds that demonstrated an increase in the half-life as well as an increase in the in vitro potency compared to 5. Reported herein is the discovery of 26, containing a (2R,4S)-4-hydroxy-4-(2,4-difluorophenyl)-pyrrolidine scaffold, which is a selective, orally bioavailable, efficacious Factor Xa inhibitor that appears suitable for a once-daily dosing (projected human t1/2 = 23 h).

CARBONYL COMPOUNDS

The invention relates to the novel compounds of formula (I), wherein D, E, G, W, X, Y, T, R and R are defined as in claim 1. The inventive compounds inhibit coagulation factor Xa and can be used in the prophylaxis and/or therapy of thrombo-embolic diseases and for treating tumors.